Home » Authors » Jim Shrine

Articles by Jim Shrine

NIH Initiates Phase III Trial Of Avicena's Creatine Agent for PD

March 23, 2007

NIH Initiates Phase III Trial Of Avicena's Creatine Agent for PD

March 23, 2007

Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent

March 22, 2007

Australian biotechnology company Avexa Ltd. parlayed positive Phase IIb data on its lead HIV compound into a funding round that will total A$75 million (US$60.1 million). (BioWorld Today)

Avexa Raises $60.1M To Fund Phase III Trials Of HIV Agent

March 22, 2007

Australian biotechnology company Avexa Ltd. parlayed positive Phase IIb data on its lead HIV compound into a funding round that will total A$75 million (US$60.1 million). (BioWorld Today)

Alethia Enters Deal With Biosite For Ovarian Cancer Antibodies

March 14, 2007

Alethia Enters Deal With Biosite For Ovarian Cancer Antibodies

March 14, 2007

Neose Raising $43.3M Through A Placement Of Stock, Warrants

March 12, 2007

Neose Raising $43.3M Through A Placement Of Stock, Warrants

March 12, 2007

Avalon, Merck Collaborate To Work On Difficult Cancer Target

March 8, 2007

Avalon, Merck Collaborate To Work On Difficult Cancer Target

March 8, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...